Page 240 - 2021_06-Haematologica-web

Letters to the Editor
Disclosures: no conflicts of interest to disclose.
Contributions: SF conceived the research, coordinated the research and interpreted the results; SF, CGA analyzed the results and SF wrote the manuscript; SF and CGA acquired and analyzed flow cytometric data; SF performed the statistical analyses; RMaf and RMar supervised the work-flow, revised the results and the manuscript critically; GD, LP, ML approved the final version of the paper.
Funding: this work was supported by Associazione Italiana per
la Ricerca sul Cancro (IG21436 RM), Progetto Dipartimenti di Eccellenza 2018-2022. SF is supported by Fondazione Umberto Veronesi, Milan, Italy. The funding bodies had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
References
1. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associat- ed with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273.
2. Riva G, Nasillo V, Tagliafico E, Trenti T, Comoli P, Luppi M. COVID- 19: more than a cytokine storm. Crit Care. 2020;24(1):549.
3. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e745.
4. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-1143.
5. Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912-1915.
6. Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Br J Haematol. 2020;190(2):e73-e76.
7. Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 sever- ity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354-2363.
8. Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol. 2020;5(48):eabd0110.
9. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irre- versible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
10. Fiorcari S, Maffei R, Audrito V, et al. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016;7(40):65968–65981.
11. Fan K, Jia Y, Wang S, et al. Role of Itk signalling in the interaction between influenza A virus and T-cells. J Gen Virol. 2012;93(Pt 5):987- 997.
12. Fiorcari S, Maffei R, Vallerini D, et al. BTK inhibition impairs the innate response against fungal infection in patients with chronic lym- phocytic leukemia. Front Immunol. 2020;11:2158.
13. Chong EA, Roeker LE, Shadman M, Davids MS, Schuster SJ, Mato AR. BTK inhibitors in cancer patients with COVID-19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res. 2020;26(14):3514-3516.
14. Zhou P, Ma B, Xu S, et al. Knockdown of Burton’s tyrosine kinase confers potent protection against sepsis-induced acute lung injury. Cell Biochem Biophys. 2014;70(2):1265-1275.
15.Florence JM, Krupa A, Booshehri LM, Davis SA, Matthay MA, Kurdowska AK. Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315(1):L52-L58.
2268
haematologica | 2021; 106(8)